

Stefano Bonora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6002286/publications.pdf>

Version: 2024-02-01

258
papers

5,193
citations

87888

38
h-index

144013

57
g-index

261
all docs

261
docs citations

261
times ranked

6245
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. <i>AIDS and Behavior</i> , 2022, 26, 2203-2211.	2.7	4
2	A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis. <i>Minerva Biotechnology and Biomolecular Research</i> , 2022, 33, .	0.5	0
3	Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. <i>Viruses</i> , 2022, 14, 753.	3.3	6
4	Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective. <i>Travel Medicine and Infectious Disease</i> , 2022, 47, 102308.	3.0	8
5	Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. <i>Frontiers in Microbiology</i> , 2022, 13, 829393.	3.5	9
6	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 103-109.	3.5	12
7	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 443-456.	4.4	3
8	Co-infection with other respiratory pathogens in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 297-298.	6.0	46
9	Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. <i>Antiviral Therapy</i> , 2021, 25, 327-333.	1.0	3
10	Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. <i>Viruses</i> , 2021, 13, 281.	3.3	51
11	On the SARS-CoV-2 'Variolation Hypothesis': No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. <i>Frontiers in Microbiology</i> , 2021, 12, 646679.	3.5	17
12	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106297.	2.5	4
13	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 665-676.	3.3	7
14	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient - A Case Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab217.	0.9	64
15	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4432-4438.	2.4	4
16	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021, 14, 460.	3.8	2
17	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021, 11, 867.	2.6	11
18	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. <i>Diagnostics</i> , 2021, 11, 869.	2.6	1

#	ARTICLE	IF	CITATIONS
19	The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. <i>Microorganisms</i> , 2021, 9, 1648.	3.6	2
20	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 914-915.	9.1	10
21	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2021, 14, 12.	3.8	7
22	Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1377.	4.4	6
23	Cerebral white matter Hyperintensities in HIV-positive patients. <i>Brain Imaging and Behavior</i> , 2020, 14, 10-18.	2.1	10
24	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 202-212.	2.0	4
25	Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. <i>Aids</i> , 2020, 34, 373-380.	2.2	17
26	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
27	Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. <i>Aids</i> , 2020, 34, 1899-1906.	2.2	7
28	Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. <i>Thrombosis Research</i> , 2020, 196, 432-434.	1.7	20
29	Good times, bad times: A diary of a physician in the COVID-19 era. <i>European Journal of Internal Medicine</i> , 2020, 77, 132-133.	2.2	0
30	A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. <i>Journal of NeuroVirology</i> , 2020, 26, 642-651.	2.1	21
31	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	2
32	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The STORE Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 290-294.	2.1	3
33	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020, 52, 447-451.	0.9	1
34	THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance. <i>Journal of Hepatology</i> , 2019, 70, e209-e210.	3.7	0
35	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
36	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46

#	ARTICLE	IF	CITATIONS
37	The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. <i>Journal of NeuroVirology</i> , 2019, 25, 887-892.	2.1	2
38	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019, 116, 23-28.	3.1	11
39	In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 321-326.	1.5	6
40	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019, 33, 1256-1260.	2.2	10
41	HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. <i>Aids</i> , 2019, 33, 665-674.	2.2	2
42	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 202-204.	1.8	2
43	<i>SLC22A2</i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1035-1043.	3.0	24
44	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
45	Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019, 19, 65-71.	2.0	6
46	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
47	The clinical pharmacology of integrase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 31-44.	3.1	6
48	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during <i>Mycobacterium genavense</i> and <i>Leishmania</i> abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 546-548.	3.0	3
49	The Outcome of HIV-Positive Late Presenters According to Detectable CMV DNA and Anti-CMV Treatment. <i>Antiviral Therapy</i> , 2018, 23, 451-456.	1.0	8
50	Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1380-1383.	2.4	4
51	CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. <i>Current HIV/AIDS Reports</i> , 2018, 15, 84-91.	3.1	16
52	Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 59-82.	3.3	36
53	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 826-827.	3.0	18
54	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	3.7	28

#	ARTICLE	IF	CITATIONS
55	Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. <i>HIV Medicine</i> , 2018, 19, 455-464.	2.2	19
56	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	3
57	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
58	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018, 24, 679-694.	2.1	3
59	Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. <i>Atherosclerosis</i> , 2018, 274, 218-226.	0.8	23
60	Effect of ABCG2 and ABCG2 Gene Polymorphisms and CSF to Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1550-1556.	2.0	11
61	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy113.	0.9	56
62	Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1146-1148.	2.4	5
63	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice) Tj ETQq1 1 0.784314 gBT /Ov 3.1	3.1	10
64	Treating HIV Infection in the Central Nervous System. <i>Drugs</i> , 2017, 77, 145-157.	10.9	13
65	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 223-230.	2.8	41
66	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19
67	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≥ 50 μ p/mL. <i>Infection</i> , 2017, 45, 521-528.	4.7	10
68	Prevalence and predictors of long corrected QT interval in HIV-positive patients. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 539-544.	1.5	19
69	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017, 18, 865-880.	1.3	13
70	Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1741-1744.	3.0	14
71	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3163-3166.	3.0	6
72	Cerebrospinal Fluid Viral Load and Neopterin in HIV-Positive Patients with Undetectable Viraemia. <i>Antiviral Therapy</i> , 2017, 22, 539-543.	1.0	17

#	ARTICLE	IF	CITATIONS
73	Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?. <i>Journal of NeuroVirology</i> , 2017, 23, 763-767.	2.1	7
74	Blood Brain Barrier Impairment in HIV-Positive Na ⁺ -ve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 187-193.	4.1	11
75	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017, 56, 355-369.	3.5	26
76	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	2.5	9
77	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. <i>PLoS ONE</i> , 2017, 12, e0189425.	2.5	6
78	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2017, 17, .	1.0	0
79	High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. <i>Current HIV Research</i> , 2017, 15, 258-265.	0.5	1
80	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2017, 17, .	1.0	4
81	Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting. <i>AIDS Reviews</i> , 2017, 19, 24-34.	1.0	6
82	What do we know about tailoring treatment with tenofovir?. <i>Pharmacogenomics</i> , 2016, 17, 531-534.	1.3	5
83	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw492.	3.0	7
84	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw512.	3.0	8
85	Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. <i>Antiviral Therapy</i> , 2016, 21, 633-635.	1.0	11
86	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 409-411.	1.1	19
87	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 117-123.	2.5	22
88	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 750-752.	1.0	2
89	Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 749-751.	2.1	4
90	HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-na ⁺ -ve patients: consideration for HCV genotyping resistance testing. <i>Infection</i> , 2016, 44, 789-792.	4.7	3

#	ARTICLE	IF	CITATIONS
91	Zika virus infection in two travelers returning from an epidemic area to Italy, 2016: Algorithm for diagnosis and recommendations. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 506-508.	3.0	7
92	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.9	13
93	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016, 30, 915-920.	2.2	12
94	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016, 497, 287-292.	5.2	10
95	Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016, 37, 3600-3609.	2.2	41
96	HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 565-576.	3.1	42
97	Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV Pls. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1330-1340.	3.0	10
98	Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 409-419.	1.8	9
99	Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. <i>Journal of NeuroVirology</i> , 2016, 22, 88-92.	2.1	40
100	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016, 16, 514-518.	2.0	24
101	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	2.5	5
102	Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. <i>Antiviral Therapy</i> , 2015, 20, 357-359.	1.0	6
103	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 695-696.	2.0	3
104	A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 839-843.	1.5	24
105	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	2.5	7
106	Automatic optimization high-speed high-resolution OCT retinal imaging at 11¼m. , 2015, , .		0
107	Cardiovascular disease in HIV patients: from bench to bedside and backwards. <i>Open Heart</i> , 2015, 2, e000174.	2.3	74
108	Acute HIV infection: Improved algorithms for HIV testing. <i>Journal of Clinical Virology</i> , 2015, 63, 51-52.	3.1	4

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1167-1176.	3.3	9
110	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural <sc>B</sc>urundi. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 801-808.	2.4	15
111	High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. <i>Atherosclerosis</i> , 2015, 240, 197-204.	0.8	89
112	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 8-11.	2.8	23
113	Heart failure in patients with human immunodeficiency virus. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 383-389.	1.5	14
114	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
115	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2572-2575.	3.0	23
116	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3074-3079.	3.0	11
117	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3096-3099.	3.0	14
118	Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. <i>Archives of Virology</i> , 2015, 160, 2881-2885.	2.1	10
119	HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 999-1008.	1.1	18
120	Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control. <i>Clinical Infectious Diseases</i> , 2015, 60, 311-317.	5.8	50
121	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146
122	Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. <i>Current HIV Research</i> , 2015, 14, 54-60.	0.5	8
123	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXAim Project. <i>New Microbiologica</i> , 2015, 38, 443-90.	0.1	6
124	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015, 23, 367-9.	1.1	3
125	Cerebrospinal fluid biomarkers in patients with plasma HIV RNA below 20 copies/mL. <i>Journal of the International AIDS Society</i> , 2014, 17, 19719.	3.0	4
126	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19771.	3.0	2

#	ARTICLE	IF	CITATIONS
127	Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. <i>Journal of the International AIDS Society</i> , 2014, 17, 19799.	3.0	1
128	Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. <i>Journal of the International AIDS Society</i> , 2014, 17, 19571.	3.0	1
129	Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. <i>Clinical Pharmacokinetics</i> , 2014, 53, 891-906.	3.5	60
130	Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2586-2588.	3.0	1
131	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014, 15, 1281-1286.	1.3	9
132	No pharmacokinetic interaction between raltegravir and amlodipine. <i>Aids</i> , 2014, 28, 1993-1995.	2.2	1
133	Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 835-836.	1.1	3
134	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915.	3.0	13
135	Local and global spatio-temporal dynamics of HIV-1 subtype F1. <i>Journal of Medical Virology</i> , 2014, 86, 186-192.	5.0	13
136	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 94, 65-70.	2.8	8
137	Intracellular Antiviral Activity of Low-Dose Ritonavir in Boosted Protease Inhibitor Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4042-4047.	3.2	16
138	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1436-1439.	3.0	5
139	Prevalence and predictors of blood-brain barrier damage in the HAART era. <i>Journal of NeuroVirology</i> , 2014, 20, 521-525.	2.1	17
140	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 241-245.	3.0	27
141	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. <i>BMC Infectious Diseases</i> , 2014, 14, 398.	2.9	13
142	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	2.0	48
143	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3061-3066.	3.0	36
144	Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. <i>BMC Anesthesiology</i> , 2014, 14, 37.	1.8	27

#	ARTICLE	IF	CITATIONS
145	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. <i>Thrombosis Research</i> , 2014, 134, 558-564.	1.7	44
146	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014, 108, 44-47.	4.1	8
147	Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients. <i>Current HIV Research</i> , 2014, 12, 339-346.	0.5	7
148	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014, 37, 285-306.	0.1	0
149	Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. <i>Clinical Infectious Diseases</i> , 2013, 56, 1677-1678.	5.8	2
150	Evaluation of a rapid antigen and antibody combination test in acute HIV infection. <i>Journal of Clinical Virology</i> , 2013, 57, 84-87.	3.1	43
151	Comment on "Higher CNS Penetration-Effectiveness of Long-Term Combination Antiretroviral Therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, e118-e119.	2.1	2
152	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1686-1688.	3.0	12
153	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 907-910.	3.0	21
154	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 482-484.	3.0	4
155	Experimental evaluation of a new system for laser tissue welding applied on damaged lungs. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 16, 577-582.	1.1	6
156	Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1840-1843.	3.2	41
157	Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. <i>European Heart Journal</i> , 2013, 34, 1432-1436.	2.2	120
158	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e80157.	2.5	35
159	Inpatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.	2.0	30
160	Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 722-728.	2.0	31
161	Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 165-170.	2.0	37
162	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2236-2242.	3.0	16

#	ARTICLE	IF	CITATIONS
163	Determinants of darunavir cerebrospinal fluid concentrations. <i>Aids</i> , 2012, 26, 1529-1533.	2.2	34
164	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 66, 376-380.	2.8	26
165	Influence of <i>CYP2B6</i> and <i>ABCB1</i> SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 134-140.	2.4	30
166	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011, 25, 1437-1439.	2.2	23
167	Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart. <i>Antiviral Therapy</i> , 2011, 16, 797-803.	1.0	9
168	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011, 16, 499-504.	1.0	9
169	<i>No pol</i> mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011, 83, 391-398.	5.0	1
170	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011, 54, 2279-2279.	7.3	25
171	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 779-788.	2.8	58
172	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 885-889.	3.0	5
173	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 192-200.	3.0	14
174	Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153.	4.0	102
175	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 688-688.	3.0	0
176	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1932-1934.	3.0	9
177	Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2976-2978.	3.2	64
178	A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. <i>Brazilian Journal of Infectious Diseases</i> , 2011, 15, 498-500.	0.6	0
179	A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 86-92.	2.0	20
180	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.	2.2	120

#	ARTICLE	IF	CITATIONS
181	Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. <i>Journal of Medical Virology</i> , 2010, 82, 1996-2003.	5.0	6
182	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 52, 774-780.	2.8	71
183	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 759-765.	1.5	38
184	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	2.5	94
185	Raltegravir Penetration in Seminal Plasma of Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2744-2745.	3.2	13
186	Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2052-2053.	3.0	3
187	Raltegravir: is a 400 mg once-daily dose enough?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 595-597.	3.0	6
188	Population Pharmacokinetic Modeling of the Association between 63396 T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	3.2	66
189	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010, 24, 931-932.	2.2	11
190	Phase control of a path-entangled photon state by a deformable membrane mirror. <i>Journal of the Optical Society of America B: Optical Physics</i> , 2010, 27, A175.	2.1	8
191	Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients. <i>Journal of Clinical Virology</i> , 2010, 47, 8-12.	3.1	16
192	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 874-875.	3.0	11
193	Molecular Typing of <i>Mycobacterium bovis</i> Strains Isolated in Italy from 2000 to 2006 and Evaluation of Variable-Number Tandem Repeats for Geographically Optimized Genotyping. <i>Journal of Clinical Microbiology</i> , 2009, 47, 636-644.	3.9	103
194	Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 575-578.	3.0	9
195	Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein Rev. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2816-2823.	3.2	18
196	Efficacy of Early Pegylated Interferon α 2b Monotherapy for Acute Hepatitis C in HIV-1 Infected Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 1636-1637.	5.8	2
197	Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation. <i>Journal of Medical Virology</i> , 2009, 81, 400-405.	5.0	49
198	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. <i>Current HIV Research</i> , 2009, 7, 425-433.	0.5	1

#	ARTICLE	IF	CITATIONS
199	Tenofovir Coadministration Is Not Associated With Lower Unboosted Atazanavir Plasma Exposure in the Clinical Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 52, 431-432.	2.1	22
200	Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. <i>Journal of Infection</i> , 2008, 57, 78-81.	3.3	14
201	Does Iatrogenic Scleroderma due to Injection-Site Reaction to Enfuvirtide Impair Absorption of the Drug?. <i>Clinical Drug Investigation</i> , 2008, 28, 305-311.	2.2	1
202	A New Assay Based on Solid-Phase Extraction Procedure with LC-MS to Measure Plasmatic Concentrations of Tenofovir and Emtricitabine in HIV Infected Patients. <i>Journal of Chromatographic Science</i> , 2008, 46, 524-528.	1.4	38
203	Drug Interactions between Warfarin and Efavirenz or Lopinavir-Ritonavir in Clinical Treatment. <i>Clinical Infectious Diseases</i> , 2008, 46, 146-147.	5.8	35
204	Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1066-1071.	3.2	17
205	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1356-1364.	3.0	13
206	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 384-387.	3.0	7
207	Association of a Single Nucleotide Polymorphism in the Pregnane X Receptor (PXR) with Reduced Concentrations of Unboosted Atazanavir. <i>Clinical Infectious Diseases</i> , 2008, 47, 1222-1225.	5.8	77
208	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1188-1190.	3.0	3
209	Even-Order Aberration Cancellation in Quantum Interferometry. <i>Physical Review Letters</i> , 2008, 101, 233603.	7.8	34
210	A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 90-94.	2.0	12
211	An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 662-669.	2.0	105
212	Interactions between antiretroviral agents and those used to treat tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 306-312.	3.8	14
213	Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 565-568.	3.0	11
214	Clinically Significant Drug Interaction between Tipranavir-Ritonavir and Phenobarbital in an HIV-Infected Subject. <i>Clinical Infectious Diseases</i> , 2007, 45, 1654-1655.	5.8	16
215	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 374-378.	2.3	22
216	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 859, 234-240.	2.3	80

#	ARTICLE	IF	CITATIONS
217	Enfuvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. <i>Aids</i> , 2006, 20, 297-299.	2.2	28
218	An Improved HPLC Fluorimetric Method for the Determination of Enfuvirtide Plasma Levels in HIV-Infected Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 110-115.	2.0	12
219	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006, 20, 1977-1979.	2.2	28
220	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 127-130.	2.3	52
221	Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 180-185.	2.1	32
222	Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 483-485.	3.0	2
223	Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 714-722.	3.0	80
224	Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 821-836.	2.4	19
225	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005, 7, 161-7.	1.0	3
226	Which agents should we use for the treatment of multidrug-resistant <i>Mycobacterium tuberculosis</i> ?. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 593-602.	3.0	111
227	The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 716-722.	1.1	60
228	Intrapulmonary Concentrations of Cefepime. <i>Critical Care Medicine</i> , 2004, 32, 1238.	0.9	0
229	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004, 18, 577-578.	2.2	7
230	Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 35-39.	2.0	49
231	Clearance of 14-3-3 Protein from Cerebrospinal Fluid Heralds the Resolution of Bacterial Meningitis. <i>Clinical Infectious Diseases</i> , 2003, 36, 1492-1495.	5.8	18
232	Ketoconazole and Lopinavir/Ritonavir Coadministration: Boosting beyond Boosting. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 941-942.	1.1	5
233	HIV-1 Phenotypic Susceptibility to Lopinavir (LPV) and Genotypic Analysis in LPV/r-Naive Subjects With Prior Protease Inhibitor Experience. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 439-447.	2.1	19
234	Treating Advanced HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 344-345.	2.1	5

#	ARTICLE	IF	CITATIONS
235	Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. <i>Aids</i> , 2003, 17, 1107-1108.	2.2	28
236	Healthy Ranges for Alanine Aminotransferase Levels. <i>Annals of Internal Medicine</i> , 2003, 138, 156.	3.9	5
237	Lopinavir Measurement in Pleural Effusion in a Human Immunodeficiency Virus Type 1-Infected Patient with Kaposi's Sarcoma. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3684-3685.	3.2	2
238	Pharmacokinetics of saquinavir co-administered with cimetidine. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 1081-1084.	3.0	21
239	Î±1-Acid Glycoprotein Levels in Human Immunodeficiency Virus-Infected Subjects on Antiretroviral Regimens. <i>Drug Metabolism and Disposition</i> , 2002, 30, 859-860.	3.3	14
240	Simultaneous Determination of Rifampicin and Efavirenz in Plasma. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 670-674.	2.0	13
241	The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 262-268.	2.4	13
242	Clinical use of lopinavir/ritonavir in a salvage therapy setting. <i>Aids</i> , 2002, 16, 2081-2083.	2.2	60
243	Pharmacokinetic Evaluation of Indinavir and Indinavir/Ritonavir-Containing Antiretroviral Regimens in a Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 574-576.	2.0	3
244	Rising temperature and the malaria epidemic in Burundi. <i>Trends in Parasitology</i> , 2001, 17, 572-573.	3.3	15
245	Identification of 54 Mycobacterial Species by PCR-Restriction Fragment Length Polymorphism Analysis of the hsp65 Gene. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2799-2806.	3.9	141
246	Mycobacterium tuberculosis transmission and HIV status. <i>Lancet, The</i> , 2000, 355, 2077.	13.7	1
247	Rapid absorption and clinical effectiveness of intragastric mefloquine in the treatment of cerebral malaria in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 573-576.	3.0	11
248	Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. <i>Journal of Infection</i> , 1999, 39, 193-197.	3.3	7
249	Granulomatous inflammation and transmission of infectious disease. <i>Trends in Immunology</i> , 1999, 20, 337-338.	7.5	1
250	Molecular typing of Mycobacterium tuberculosis. <i>Lancet, The</i> , 1999, 353, 1442.	13.7	6
251	Fatal primary multidrug-resistant tuberculosis in a heart transplant recipient. <i>Transplant International</i> , 1998, 11, 305-307.	1.6	17
252	Highly active antiretroviral therapy. <i>Lancet, The</i> , 1998, 351, 1056.	13.7	16

#	ARTICLE	IF	CITATIONS
253	Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands. <i>Acta Tropica</i> , 1998, 70, 25-33.	2.0	9
254	Tuberculosis Among Refugees and Displaced People at the Burundiâ€Rwanda Border. <i>Clinical Infectious Diseases</i> , 1998, 26, 500-501.	5.8	4
255	Failure of Prophylaxis against PCP in Patients with HIV Infection. <i>AIDS Patient Care and STDs</i> , 1998, 12, 843-848.	2.5	6
256	Microsporidium Species in Pulmonary Cavity Lesions of AIDS Patient Infected with <i>Rhodococcus equi</i> . <i>Clinical Infectious Diseases</i> , 1997, 25, 926-927.	5.8	10
257	Fatal Pneumothorax Complicating BAL in a Bone Marrow Transplant Recipient with Bronchiolitis Obliterans. <i>Chest</i> , 1997, 111, 1468-1469.	0.8	8
258	The ParaSightâ„¢-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of <i>Plasmodium falciparum</i> malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 403-405.	1.8	28